Skip to main content

RT @synovialjoints: IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in ◦ total spinal pain (SP) ◦ nocturnal SP

Nov 13, 2022 7:53 am
Social Author Name
Dr. Antoni Chan
Tweet Content
IL17A/Fi BImekizumab BKZ to Wk 24 achieved reduction in ◦ total spinal pain (SP) ◦ nocturnal SP ◦ morning stiffness (BASDAI) ◦ fatigue (FACIT-F) Deodhar et al, BE MOBILE 1,2 Abst 0409 https://t.co/vpCrG2COuB#ACR22 @RheumNow
Show on Archive Page
On
Display in Search Results
On
PDQ
Off
×